B/F/TAFSwitching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Inclusion Criteria:

1. Participant is ≥19 years of age infected with HIV-1
2. Participant has an undetectable viral load <40 copies/mL at screening with any CD4 count and has exhibited any, or all of the following:

1. Transient HIV viremia (episodes of HIV viral load between 40-1000 copies/mL) in the past 12 months, OR Virologic breakthrough (HIV viral load > 1000 copies/mL) in the past 12 months, OR Documented instances of non-adherence for a period of more than 7 days or...
2. Participant is currently on multi-tablet HIV antiretroviral therapy, including multi-tablet regimens and/or two drug combinations (dual therapy)
3. Participant has a history or current indication of illicit drug use.
4. Patients infected with HCV and or HBV can be included in this study.
5. If female, participant must have a negative pregnancy test and agree to use, for the duration of the study, a method of birth control that has a history of proven reliability as judged by the investigator.

Exclusion Criteria:

1. They have any documented history of integrase inhibitor resistance
2. They exhibit any of the following:

1. Creatinine Clearance Rate < 30 ml/min
2. Hemoglobin < 10.0 g/dL
3. Absolute neutrophil count <750 cells/mL
4. Platelet count < 50,000 /mL
5. ALT or AST >5x upper limit of normal (ULN)
6. Creatinine > 1.5x ULN
3. They are taking medication that is contraindicated with any component of B/F/TAF.
4. They are pregnant or breastfeeding.
5. They do not/have not ever used any form of illicit drug use.